Paroxysmal Nocturnal Haemoglobinuria
·MeSH: Hemoglobinuria, Paroxysmal
Prevalence
5.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| Ravulizumab | ASTRAZENECA PLC (AZN) |
Frequently asked questions
How many drugs are in development for Paroxysmal Nocturnal Haemoglobinuria?
BioSniper tracks 1 drug in development for Paroxysmal Nocturnal Haemoglobinuria across 1 company.
How many clinical trials target Paroxysmal Nocturnal Haemoglobinuria?
There are 1 clinical trial targeting Paroxysmal Nocturnal Haemoglobinuria tracked by BioSniper.
What is the prevalence of Paroxysmal Nocturnal Haemoglobinuria?
The estimated prevalence of Paroxysmal Nocturnal Haemoglobinuria is approximately 5.0 per 100,000 population.
Deep-dive into Paroxysmal Nocturnal Haemoglobinuria
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis